Central Serous Retinopathy risk factors and efficacy of Dorzolamid drop

Central Serous Chorioretinopathy risk factors and efficacy of Dorzolamid drop in treatment of patients who attended to ophthalmology clinic of Valiasr hospital of Birjand city in the years 2016_2018

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180703040323N1

Enrollment

Registered

2019-01-12

Start date

2015-12-22

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Retinopathy. Central serous chorioretinopathy

Interventions

Intervention 1: Intervention group: Dorzolamid drop 2% uses twice a day about 3 weeks. Intervention 2: Control group: follow up for about 3 weeks without anything.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients that come to ophtalmology clinic of Valiasr hospital that have definite diagnose of Central Serous Retinopathy with imaging

Exclusion criteria

Exclusion criteria: Every kind of other Retinopathies

Design outcomes

Primary

Measure	Time frame
Visual Acuity and OCT. Timepoint: Three weeks. Method of measurement: Snellen chart and OCT.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReyhane Ebrahimi

Birjand University of Medical Sciences

akhoundi_1358@bums.ac.ir+98 56 3244 8393

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026